Niacin Tablet, Extended Release
NDC Package 70752-296-09

11-digit billing NDC: 70752029609
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Niacin tablets is therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. This formulation utilizes a tablet, extended release delivery system. Marketed by Quagen Pharmaceuticals Llc, this product is identified by NDC 70752-296 and is authorized under FDA application ANDA203899.

Identification & Billing

NDC Package Code
70752-296-09
Package Description
90 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
70752-296
11-Digit Billing Format
70752029609
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Niacin
Non-Proprietary Name
Niacin
Substance Name
Niacin
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
NIACIN 1000 mg/1
Pharmacologic Class
Usage Information
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.Niacin extended-release tablets are indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction.In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease.Niacin extended-release tablets in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia.Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.Limitations of UseAddition of niacin extended-release tablets did not reduce cardiovascular morbidity or mortality among patients treated with simvastatin in a large, randomized controlled trial (AIM-HIGH) [see Warnings and Precautions (5.1)].

Regulatory & Marketing

Labeler Name
Quagen Pharmaceuticals Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA203899
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-06-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70752-296-09 identifies a specific commercial package of 90 tablet, extended release in 1 bottle of Niacin, a human prescription drug labeled by Quagen Pharmaceuticals Llc. This tablet, extended release is formulated for oral use and contains niacin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Quagen Pharmaceuticals Llc on August 06, 2026. The current certification is valid through December 31, 2027.

How is this Quagen Pharmaceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70752029609. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70752-296-09
11-Digit CMS (5-4-2)
70752-0296-09

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.